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A B S T R A C T
We have previously shown that the human follicular lymphoma cell line, HF28GFP, is sensitive to TRAIL-
mediated apoptosis. Nevertheless, when the same cells overexpress anti-apoptotic Bcl-2 family protein, Bcl-xL
(HF28Bcl-xL), they become resistant to TRAIL. Thus, these cell lines help us to investigate the action of novel
apoptosis inducing candidate drugs. In the present study, we examined the effects of MG-132 (a proteasome
inhibitor), LiCl (a glycogen synthase kinase-3 inhibitor) and/or TRAIL on pro-apoptotic Bcl-2 family proteins
such as Bim and Bid. Here we demonstrate that the combination of MG-132 and TRAIL induced significant
apoptotic cell death in both cell lines, HF28GFP and HF28BclxL. Apoptosis correlated with a decrease of
phospho-ERK1/2, the accumulation of Bim and translocation of truncated Bid (tBid) and jBid. In addition, the
combination of MG-132 and TRAIL seemed to target other apoptotic factors, which led to the accumulation of
active capsase-3. Furthermore, co-stimulation of LiCl and TRAIL induced apoptosis in HF28GFP cells. However,
HF28Bcl-xL cells were far less sensitive to the combinatorial effects of LiCl and TRAIL. Interestingly, we observed
that LiCl did not target Bim and Bid proteins. In conclusion, these data show that targeting of pro-apoptotic Bcl-2
family proteins simultaneously through a selective proteasome inhibition might help to overcome TRAIL re-
sistance caused by overexpression of anti-apoptotic Bcl-2 family proteins. Moreover, the data may provide new
strategies to develop targeted therapies against lymphomas.
1. Introduction
Apoptosis is a type of programmed cell death that plays an essential
role in the development and homeostasis of normal tissues. The two
main apoptotic pathways are the death receptor pathway (extrinsic
pathway) and the mitochondrial pathway (intrinsic pathway). These
pathways are executed by caspases which eventually lead to the demise
of a cell [1].
The death receptor signaling pathway is initiated by cytotoxic li-
gands such TRAIL (tumor necrosis factor-related apoptosis inducing
ligand) and Fas. The activation of transmembrane TRAIL death re-
ceptors DR4 or DR5 by TRAIL leads to the formation of death-inducing
signaling complex (DISC), where caspase-8 is activated. The active
caspase-8 then cleaves and activates caspase-3, which results in apop-
tosis. Moreover, TRAIL selectively initiates apoptosis in a variety of
tumor cells but not in normal cells. This special feature of TRAIL makes
it a promising candidate for treatment of cancers [2,3].
Mitochondrial signaling pathway, however, is activated by a variety
of non-receptor-mediated apoptotic stimuli such as cytotoxic drugs.
This pathway is mainly regulated by Bcl-2 family proteins, a group of
structurally related proteins. The Bcl-2 family proteins can be classified
into three groups; 1) anti-apoptotic proteins such as Bcl-xL, Bcl-2, and
Mcl-1, 2) multi-BH pro-apoptotic effector proteins, Bax and Bak, and 3)
BH3-only proteins (pro-apoptotic sensitizers/activators) such as Bim
and Bid [4].
The intrinsic apoptotic stimuli lead to the activation of pro-apop-
totic Bcl-2 family proteins and/or down-regulation of anti-apoptotic
proteins. For instance, up-regulation of Bim results in the activation of
pore forming Bcl-2 family proteins, Bax/Bak either by 1) direct acti-
vation – the binding of Bim with Bax/Bak, or 2) indirect activation –
freeing Bax/Bak from anti-apoptotic Bcl-2 family proteins. This phe-
nomenon triggers mitochondrial outer membrane permeabilization
(MOMP), thereby apoptotic proteins such as cytochrome c, and smac
are released from the mitochondrial interspace into the cytosol. The
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formation of cytochrome c, Apaf-1 and ATP complex leads to the acti-
vation of caspase-9. Moreover, the released smac neutralizes the anti-
apoptotic effect of XIAP (X-linked inhibitor of apoptosis protein).
Consecutively, the activation of caspase-3 by caspase-9 leads to apop-
tosis [5,6].
As Bim is an important protein for the induction of apoptosis,
resting cells regulate the turnover of this protein through phosphor-
ylation and degradation by the survival kinase, ERK1/2. Inhibition of
Bim degradation, therefore, can lead to cell death [7–9].
The cells which do not require the involvement of mitochondria in
Fas/TRAIL-mediated apoptosis are called type I, whereas the cells that
depend on the engagement of mitochondria are known as type II
[10,11]. Bid has an important role in both type I and type II cells be-
cause caspase-8 mediated cleavage of Bid, truncated Bid (tBid – 15 kDa)
connects the death receptors-induced signaling to mitochondria. tBid
translocation into the mitochondria, thus, leads to the releases apop-
totic factors. Moreover, it is interesting that JNK might induce caspase-
8 independent cleavage of Bid at a distinct site to generate an inter-
mediate product jBid (21 kDa) and the translocation of jBid to mi-
tochondria preferentially releases smac to the cytosol [12].
XIAP protein suppresses apoptotic pathways. It binds and in-
activates both caspase-9 and caspase-3. This special feature of XIAP
enables it to prevent death receptor- and mitochondrial-mediated
apoptosis. Furthermore, it has been shown that inhibition of XIAP
switches type II signaling to type I signaling [13].
The proteasome is a large catalytic complex that is responsible for
most non-lysosomal intracellular protein degradation of misfolded/
damaged proteins. It also regulates protein turnover [14]. The protea-
some, thus, regulates cellular homeostasis by maintaining the normal
functions of cellular proteins. The proteasome, however, is also play an
important role in the progression of cancer because it regulates critical
proteins such as transcription factors. Therefore, proteasome inhibition
is an attractive target for the development of anti-cancer therapies [15].
Proteasome inhibition can lead to cellular cytotoxicity through
several mechanisms including, Bim accumulation by decreasing the
amount of phospho-ERK1/2 [16], inhibition of NF-kB activity, and
stabilization of p53. MG-132 (a proteasome inhibitor) is commonly
used to investigate the proteasome activity in a range of cell types [17].
Moreover, MG-132 enhances TRAIL-induced apoptosis through up-
regulation of DR5 in cancer cells [18].
Glycogen synthase kinase-3β (GSK3β) involved in multiple cellular
processes including proliferation, glucose regulation and apoptosis
[19]. Inhibition of GSK-3 by LiCl is found to augment the apoptotic
effect of TRAIL in human lung carcinoma cells through up-regulation of
death receptors DR4 and DR5 [20].
Overexpression of anti-apoptotic Bcl-2 family proteins prevents
mitochondria-mediated apoptosis by blocking the permeabilization of
outer mitochondrial membrane. We have previously shown that TRAIL
induces apoptosis in HF28GFP cells (Type II cell model) but the apop-
tosis is completely prevented by overexpression of Bcl-xL (HF28Bcl-xL
cells) [10]. In the present study, we examined the effects of apoptosis
inducing agents: MG-132, LiCl, and/or TRAIL on Bid, Bim, and XIAP
using HF28GFP cells (vector control) and HF28Bcl-xL cells.
2. Materials and methods
2.1. Cell lines and culture conditions
The origin and characteristics of human follicular lymphoma cell
lines, HF28GFP and HF28Bcl-xL have been previously described [21].
The cells were cultured in RPMI 1640 medium (Lonza, Belgium) sup-
plemented with 5% heat inactivated fetal bovine serum (GIBCO, In-
vitrogen, USA). 2 mM L-glutamine (Lonza), 106 U/ml streptomycin,
106 U/ml penicillin (Lonza), 10mM HEPS buffer (Lonza), 0.1 mM
nonessential amino acids (Lonza), 1 mM Na-pyruvate (Lonza), 20 μM 2-
mercaptoethanol (Fluka-Chemie, Buch, Switzerland) at 37 °C in a 5%
CO2 humidified atmosphere.
2.2. Cell treatments
HF28GFP and HF28Bcl-xL cells were seeded on 6 or 12-well flat
bottom polystyrene cell culture plates (Corning Inc. NY, USA) and
treated with 50 ng/ml His-tagged recombinant human soluble killer
TRAIL™ (Enzo life sciences, USA), 50mM LiCl, (Sigma-Aldrich, USA)
1 μM MG-132 (Calbiochem, USA), 50 μM caspase-8 specific inhibitor, Z-
IETD-FMK (Calbiochem, USA), 20 μM JNK specific inhibitor, SP600125
(Sigma-Aldrich, USA).
2.3. Flow cytometric analysis of apoptotic cells
Apoptotic cells were determined by flow cytometric analysis after
propidium iodide (PI) staining. Cells with sub-G1 DNA content/hypo-
diploid cells were considered as apoptotic. Fixation and staining of cells
were performed according to a standard protocol. In brief, at the end of
stimulation times, samples containing one million cells were collected,
resuspended in ice-cold PBS and fixed with ice-cold 70% V/V ethanol.
After overnight incubation at +4 °C, cells were centrifuged at
1500 RPM for 10min, resuspended in PBS containing 150 μg/ml
RNAase (Sigma, USA) and incubated for 1 h at +50 °C. PI (Molecular
Probes, Sigma) was added to the final concentration of 8 μg/ml and
incubation was further continued 2 h at +37 °C. FACSCanto II flow
cytometer with FACSDiva version 6.1.2 software (Becton Dickinson,
USA) and FlowJo v10 software were used for the analysis.
2.4. Detection of changes in mitochondrial membrane potential
Depolarization of mitochondrial membrane was detected by TMRM
(methyl ester of tetramethylrhodamine) staining. After incubation of
cells with stimuli, 5× 105 cells were collected and stained with 100 nM
TMRM (Molecular Probes) for 20min at +37 °C in the dark. After
staining, the cells were immediately analyzed using a FACSCanto II
flow cytometer (Becton Dickinson). The fluorescence excitation and
emission maxima are 548 nm and 574 nm, respectively. The forward
and side scatters were used to gate living or early apoptotic cells.
2.5. Preparation of total cell lysates
At the end of stimulation times, 2× 106 cells were collected, wa-
shed in phosphate buffered saline (PBS) and centrifuged (600× g,
5 min). The cell pellet was resuspended with lysis buffer containing
20mM Tris-HCl (pH 8.0), 2 mM EDTA, 3% NP-40, 100mM NaCl,
50mM NaF, 1mM PMSF, 1mM VO4, 5 μg/ml aprotinin, and 5 μg/ml
Leupeptin. After 1 h incubation on ice, samples were centrifuged (10
000× g, 15min,+ 4 °C). The protein concentration of the lysates was
measured, equalized with sodium dodecylsulfate- polyacrylamide gel
electrophoresis (SDS-PAGE) buffer (0.125M Tris-Hcl pH 6.8, 4% SDS,
20% glycerol, 10% 2-mercaptoethanol, bromophenol blue) and boiled
for 5min.
2.6. Preparation of mitochondrial and cytosolic fractions
Mitochondrial and cytosolic fractions were separated by an Apoalert
cell fractionation kit (Clontech Laboratories, Inc., USA) according to the
manufactureŕs protocol. In brief, 2× 107 cells were collected and wa-
shed with wash buffer. The cell pellet was resuspended in 0.8mL
fractionation buffer containing protease inhibitors and dithiothreitol
(DTT) and incubated on ice for 10min. Subsequently, cells were
homogenized by passing the cell suspension through a 27G syringe
needle. The homogenate was centrifuged (700× g, 10min, +4 °C). The
remaining supernatant was centrifuged (10 000× g, 25min, +4 °C).
The supernatant (cytosolic fraction) was collected and the pellet (mi-
tochondrial fraction) was resuspended in 0.1mL fractionation buffer.
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2.7. Immunoblotting analysis
Equal amounts of protein were separated on a 12% or 15% SDS-
PAGE gel and transferred to nitrocellulose membranes (GE Healthcare
Life sciences, UK). Membranes were blocked with 1X TBS containing
3% BSA and 0.1% Tween-20 at room temperature. Then the membranes
were incubated overnight at +4 °C with the primary antibodies (ati-
caspase-8, anti-caspase-3, anti-Bid, anti-Bim, anti-phospho-ERK1/2,
total ERK1/2, anti-phospho-BimEL (Ser77), anti-XIAP, anti-cytochrome
c and anti-actin). Then the membranes were washed three times with
1X TBS and incubated with horseradish peroxidase (HRP)-conjugated
goat anti-rabbit antibody (Zymed laboratories Inc., USA) diluted in 3%
BSA for 40min at room temperature. The membranes were washed
three times with 1X TBS. Finally, the membranes were developed for
appropriate time period that yields the desired results using enhanced
chemiluminescence detection system (GE Healthcare). Immunoblotting
was done in duplicates.
2.8. Densitometry
The films were scanned and relative protein amounts were quanti-
fied using Quantity One Software. Immunoblotting results were nor-
malized by actin values for each sample. A change in protein band in-
tensities of the treated sample was compared to the control sample.
Differences in protein band intensities were calculated and shown in
fold.
2.9. Cell count
Live and dead cells were counted using hemocytometer. The cells
were diluted 1:5 and stained with Erythrocin B. The dead cells/apop-
totic cells stained pink, whereas the live cells remain unstained.
2.10. Statistical analysis
Statistical analysis was performed using GraphPad Prism5. The
statistical difference between groups was determined with student’s t-
test. P values< 0.05 were considered statistically significant.
3. Results
3.1. The combination of TRAIL with MG-132 or LiCl induces apoptosis in
HF28GFP cells
It has been shown that MG-132 or LiCl enhances TRAIL-mediated
apoptosis [18,20]. In this study, we examined whether the combination
of TRAIL with MG-132/LiCl could enhance apoptosis in HF28GFP cells.
Cells were cultured in medium containing LiCl, MG-132 and/or TRAIL.
After incubation cells were collected for analysis. Mitochondrial depo-
larization and Sub-G1 DNA content were measured by TMRM and PI
staining, respectively. The proportion of cells with collapsed mi-
tochondrial membrane potential were 5% (LiCl), 20% (MG-132), 45%
(TRAIL), 75% (LiCl+TRAIL) and 65% (MG-132+TRAIL) (Fig. 1A). In
addition, the proportion of apoptotic cells was 3% (LiCl), 10% (MG-
132), 40% (TRAIL), 70% (TRAIL+ LiCl) and 60% (TRAIL+MG-132)
(Fig. 1B). MG-132 enhanced TRAIL-induced apoptosis (TRAIL vs MG-
132+TRAIL) (P < 0.01). Moreover, the live cells were counted. The
proportion of viable HF28GFP cells after the treatment of TRAIL,
TRAIL+ LiCl, TRAIL+MG-132 were 68%, 38%, and 47%, respec-
tively. The proportion of viable HF28Bcl-xL cells after the treatment of
TRAIL+ LiCl, and TRAIL+MG-132 were 94% and 71%, respectively
(Fig. 2A). In addition, cell viability was analyzed by flow cytometry
after PI staining. The viable cells were discriminated from apoptotic
cells by analyzing dot-blot forward scatter (FSC) vs PI/PE (Fig. 2B).
Cytochrome c release from the mitochondria and capase-3 activation
were measured by immunoblotting from cytosolic extracts. MG-132 or
TRAIL induced cytochrome c (cyt c) release to the cytosol and they also
activated caspase-3. Moreover, the release of cyt c and caspase-3 acti-
vation was higher in the combination of TRAIL and MG-132 (Fig. 3A
and B). Similarly, MG-132 or TRAIL induced the activation of caspase-8
and the level of active caspase-8 was increased when MG-132 or LiCl
was combined with TRAIL (Fig. 3B).
3.2. The combination of MG-132 and TRAIL sensitizes HF28Bcl-xL cells to
apoptosis
The combination of TRAIL with LiCl/MG-132 resulted in synergistic
apoptosis in HF28GFP cells. Therefore, we further examined their
apoptotic effects in TRAIL resistant HF28Bcl-xL cells. Cells were cul-
tured in medium containing LiCl, MG-132 and/or TRAIL for 8 h.
Mitochondrial depolarization and Sub-G1DNA content were analyzed.
The proportion of cells with collapsed mitochondrial membrane po-
tential was 4% (LiCl+ TRAIL) and 15% (MG-132+TRAIL) (Fig. 1A).
Moreover, consistent with the membrane potential status, the combi-
nation of TRAIL and LiCl induced apoptosis (10% cell death) whereas,
the combination of TRAIL and MG-132 resulted in significant apoptosis
as the proportion of apoptotic cells was 35% (TRAIL vs TRAIL+MG-
132) (p < 0.001) (Fig. 1B). In order to determine whether the small
proportion of apoptotic cells observed in LiCl+ TRAIL treated cells
were due to a delayed response, the cells were incubated for 24 h. We
found that an extended stimulation of cells increased cell death slightly,
as the proportion of apoptotic cells increased from 10% (LiCl+TRAIL
8 h) (Fig. 1B) to 15% (LiCl+TRAIL 24 h) (Fig. 2C). However, the
combination of MG-132 and TRAIL increased the proportion of apop-
totic cells from 35% (8 h stimulation) (Fig. 1B) to 55% (24 h stimula-
tion) (Fig. 2C). Furthermore, the combination of LiCl with TRAIL in-
duced caspase-8 cleavage but not p12 caspase-3 (Fig. 3C). In addition,
TRAIL alone induced the activation of caspase-8 but this led to an in-
termediate caspase-3 cleavage product, p20. Nevertheless, the active
form of caspase-3, p17 and p12 were observed when MG-132 was
combined with TRAIL (Fig. 3C).
3.3. Caspase-8 has no role in MG-132-induced Bid cleavage
Co-stimulation of MG-132 and TRAIL resulted in apoptosis in
HF28Bcl-xL cells partly through mitochondria. Therefore, we in-
vestigated their effects on Bcl-2 family proteins such as Bid and Bim.
Cells were incubated with MG-132 and/or TRAIL. After incubation cells
were collected, proteins were isolated and immunoblotting was per-
formed. Interstingly, stimulation of cells with MG-132 resulted in the
cleavage of full length Bid into an intermediated Bid product (jBid)
(Fig. 4B), whereas TRAIL, as expected produced truncated bid (tBid) in
both cell types (Fig. 4A and B). Moreover, to examine whether caspase-
8 was involved in the production of jBid, cells were incubated with
caspase-8 specific inhibitor, Z-IETD for 1 h prior to the addition of MG-
132 for 8 h. Furthermore, in order to ensure that Z-IETD-FMK was ac-
tively functioning, HF28GFP cells were treated with the inhibitor 1 h
prior to the addition of TRAIL for 4 h. Z-IETD-FMK completely pre-
vented TRAIL-induced apoptosis in HF28GFP cells (vector control)
(Fig. 4D), whereas the inhibitor did not prevent the production of jBid
(Fig. 4C). In addition, JNK has been linked with production of jBid,
however, in HF28Bcl-xL cells a JNK-specific inhibitor, SP600125, led to
cell death (Data not shown).
3.4. MG-132 leads to the accumulation of Bim
We and others have previously shown that ERK is an important
player in mediating phosphorylation of Bim to confer cell survival
[7,22]. Moreover, inhibition of Bim degradation by MG-132 sensitizes
cancer cells to cell death [8]. Therefore, we examined whether MG-132
prevents ERK-mediated degradation of Bim or decreases phospho-
ERK1/2. The amount of Bim was analyzed by immunoblotting. The
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amount of BimEL protein decreased in control cells, whereas MG-132
led to the accumulation of BimEL in both cell lines (Fig. 4E). Moreover,
the expression of phospho-ERK1/2, total ERK1/2 and phospho-Bim
(Ser77) were analyzed (Fig. 4E). MG-132 significantly decreased the
level of phospho-ERK1/2 without affecting the total amount of ERK1/2
(Fig. 4E). Moreover, MG-132 decreased the amount of downstream
target protein, phospho-BimEL (Ser77). However, LiCl did not result in
accumulation of Bim (data not shown).
3.5. Down-regulation of XIAP does not act as switch between type I and type
II TRAIL-induced apoptosis
It has been shown that XIAP regulates the switch from type II to type
I signaling in Fas-induced apoptosis [23]. We, therefore, investigated
the effect of LiCl, MG-132 and/or TRAIL on XIAP protein level in
HF28Bcl-xL cells. Cells were stimulated with these apoptotic stimuli.
After stimulation cells were collected, proteins were isolated and
Fig. 1. The effects of LiCl, MG-132 and/or TRAIL-mediated apoptosis in human follicular lymphoma cells. Vector control HF28 cells (green fluorescent protein [GFP]) and HF28 cells
overexpressing Bcl-xL were treated with the indicated apoptotic stimuli for 8 h. After incubation cells were collected for analysis. (A) Mitochondrial membrane potential collapse was
measured by flow cytometry using TMRM. The TMRM analysis of control (Co) and TRAIL is presented. The same gating strategy was used in all TMRM analysis. (B) Sub-G1 DNA contents
were analyzed by flow cytometry after PI staining. Data are presented as mean ± SEM from three independent experiments. The statistical significance of difference was determined
using student’s t-test. (C) Cell cycle analysis for control cells and cells treated with TRAIL, TRAIL+ LiCl, and TRAIL+MG-132 is presented. The stages of cell cycle: Sub-G1, G0/G1, S,
G2/M are indicated in the histogram. The proportion of DNA content of cells at different stages of cell cycle is shown above the histogram (Table 1). The same gating strategy was used in
all PI analysis.
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immunoblotting was performed. Interestingly, the combination of LiCl
and TRAIL led to a significant down-regulation of XIAP amount (the
relative amount in fold compared to the control was 0.35) (Fig. 3D),
however, HF28Bcl cells were far less sensitive to apoptosis was not
induced (Fig. 1B). In addition, MG-132 in combination with TRAIL
slightly decrease the amount of XIAP (the relative amount in fold
compared to the control was 0.85) (Fig. 3D).
4. Discussion
In the present study, we demonstrate that MG-132 or LiCl enhanced
TRAIL-mediated apoptosis in HF28GFP cells. However, in contrast to
LiCl, MG-132 strongly sensitized HF28Bcl-xL cells to TRAIL because the
proportion of LiCl- and TRAIL-induced apoptotic cells was 3.5 times less
than the proportion of apoptotic cells after MG-132 and TRAIL treat-
ment (Fig. 1Figs. 1B and Fig. 22C). Therefore, we further investigated
the role of MG-132 in apoptosis. MG-132 is a proteasome inhibitor and
can target a variety of molecular pathways. However, we mainly fo-
cused on its effect on XIAP and pro-apoptotic Bcl-2 family proteins (Bid
and Bim). We choose these proteins because of their critical importance
in mitochondrial-mediated apoptosis (Fig. 5).
MG-132 produced an intermediate cleavage product of full length
Bid, jBid, in HF28Bcl-xL cells. In addition, MG-132 decreased the level
of phospho-ERK1/2, thereby preventing degradation of BimEL
(Fig. 4E). These findings show that MG-132 has broader range of effects
than simply inhibiting the proteasome pathway. Consistent with our
findings, it has been shown that MG-132 reduces the amount of
phospho-ERK1/2 [24]. Furthermore, TRAIL induced tBid. Therefore,
the combination of MG-132 and TRAIL led to the translocation of jBid,
tBid and the accumulation of Bim. As a result, mitochondria were de-
polarized. The translocation of either jBid or tBid, however, was not
enough to depolarize the mitochondria or induce apoptosis.
It is interesting that we observed jBid only in HF28Bcl-xL cells but
not in HF28GFP cells. These results indicate that when mitochondria
were fully protected by overexpressed Bcl-xL, MG-132 might activate
an apoptotic pathway which resulted in the production of jBid. JNK is a
key regulator of many cellular events including apoptosis [25]. As a
pro-apoptotic kinase, it is linked to the production of jBid. However,
JNK specific inhibitor, SP600125, accelerated apoptosis (data not
shown) in HF28Bcl-xL cells indicating that JNK has a pro-survival role
Fig. 2. Viable cells count. (A) The cells were incubated with LiCl, MG-132,
TRAIL, TRAIL+ LiCl, and TRAIL+MG-132 for 8 h. At the end of stimu-
lation time, cells were collected and stained with Erythrocin B and counted
using hemocytometer. Data are presented as mean ± SEM from three
independent experiments. (B) Live cells and apoptotic cells were analyzed
by flow cytometry. PE vs FSC gating strategy was used to discriminate the
cells. (C) HF28Bcl-xL cells were incubated with LiCl, MG-132, TRAIL,
TRAIL+ LiCl, and TRAIL+MG-132 for 24 h. Sub-G1 DNA contents were
analyzed by flow cytometry after PI staining. Data are presented as
mean ± SEM from three independent experiments.
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in HF28 cells. Furthermore, caspase-8 has no role in producing jBid, as
caspase-8 specific inhibitor Z-IETD-FMK did not prevent the production
of jBid.
Moreover, MG-132 induced active form of caspase-8 (p18) was only
seen in HF28GFP but not in HF28Bcl-xL. It is well-known that caspase-8
can be activated either by death receptor stimulation or caspase-3 [26].
Therefore, based on our findings, we suggest that the activation of
caspase-8 in HF28GFP cells was mediated by active caspase-3. Firstly,
we did not observe MG-132-mediated activation of caspase-3/caspase-8
in HF28Bcl-xL cells. Thus, caspase-3 to caspase-8 activation feedback
loop was missing. Secondly, as MG-132 is not a cognate ligand to death
receptors (TRAIL-R and Fas-R), it is unlikely that MG-132 leads to
caspase-8 activation through these receptors.
In HF28GFP cells, the proportion of TRAIL-induced apoptotic cells
and cells with depolarized membrane were 40% and 45%, respectively.
Whereas in HF28Bcl-xL cells, the proportion of MG-132+TRAIL-in-
duced apoptotic cells and cells with depolarized membrane were 35%
and 15%, respectively. These results show that the proportion HF28Bcl-
xL cells with depolarized membrane was four times less than the pro-
portion of HF28GFP cells with depolarized membrane. Nevertheless,
the proportion of apoptotic cells between the two cell lines were
comparable. Therefore, we suggest that MG-132- and TRAIL-mediated
apoptosis was largely depend on type I signaling pathway. In addition,
the results analyzed by viable cells count and the PI staining were also
Fig. 3. The effects of LiCl, MG-132 and/or TRAIL on cytochrome c release,
caspase activation and XIAP protein level. The mitochondrial and cytosolic
proteins were separated as described in “Materials and methods”. (A)
Cytochrome c release in HF28GFP and HF28Bcl-xL cells was detected by
immunoblotting. (B) Activation of caspase-8 and caspase-3 in HF28GFP
cells was analyzed by immunoblotting. (C) Activation of caspase-8 and
caspase-3 in HF28Bcl-xL cells was analyzed by immunoblotting. (D) XIAP
protein level in HF28Bcl-xL cells were detected by immunoblotting.
Moreover, XIAP protein level of control, and cells treated with LiCl, MG-
132, TRAIL, TRAIL+ LiCl and TRAIL+MG-132 was quantified. Antibody
against actin was used to ensure that equal amount of protein was loaded
on the gel. These samples were analyzed from the same experiments which
were used for TMRM and PI analysis.
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comparable.
In mitochondrial-induced apoptosis, we always observed the active
form of caspase-3, P17 [27,28]. However, in death receptor (TRAIL-
induced apoptosis), the intermediate caspase-3 product, p20 is detected
(Fig. 3B and C). This non-apoptotic caspase-3 product should further be
processed to induce apoptosis. Interestingly, in the present study, we
demonstrate that the combination of MG-132/LiCl with TRAIL induced
a massive mitochondrial depolarization. As a result, a significant
amount of p17 was produced, which led to cell death. Clearly, these
data show that the apoptotic factors from mitochondria are required to
eliminate the inhibitor of p20. We also show that the combination of
MG-132 and TRAIL induced mitochondrial depolarization in HF28Bcl-
xL cell. We, therefore, suggest that this event might contribute to the
activation of p17.
It has been shown that inhibition of XIAP protein in mitochondria-
dependent type II cells switches type II to type I death receptor
Fig. 4. MG-132 produces an intermediate Bid cleavage, jBid and/or an
accumulation of Bim in HF28Bcl-xL/HF28GP cells. (A) Full length Bid and
tBid were detected by immunoblotting from cytosolic/mitochondrial ex-
tracts of HF28GFP cells. (B) Full length, jBid and tBid were detected by
immunoblotting from cytosolic/mitochondrial extracts of HF28Bcl-xL
cells. These samples were analyzed from the same experiments which were
used for TMRM and PI analysis. (C) HF28Bcl-xL cells were treated with
caspase-8 specific inhibitor, Z-IETD-FMK for 1 h prior to the addition of
MG-132 for 8 h. In addition, cells were also treated with Z-IETD-FMK for
1 h prior to the addition of TRAIL for 4 h. After the incubation cells were
collected for analysis. Total cell lysates were prepared for immunoblotting.
Full length Bid and jBid were detected by immunoblotting. Actin was also
used. (D) Sub-G1 DNA contents of the cells were analyzed. (E) HF28GFP
and HF28Bcl-xL cells were treated with MG-132 for 8 h. After incubation
the cells were collected and total cell lysates were prepared. The levels of
phospho-ERK1/2, total ERK1/2, Bim, phospho-BimEL were analyzed.
Actin was also used.
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signaling [23]. Moreover, XIAP is known to bind and prevent caspase-3
activation [29]. In this study, we show that the combination of
TRAIL+ LiCl significantly down-regulated XIAP amount. Nevertheless,
these apoptotic stimuli failed to produce the active caspase-3 cleavage,
p12. However, we speculate that a very low proportion of apoptotic
HF28Bcl-xL cells which resulted from TRAIL+ LiCl was due to the
activation of low level of p17. These data indicate that XIAP is not a
critical protein in switching type II to type I signaling in HF28 cells.
Thus, a protein which bind to p20 remains to be investigated. However,
it is important to mention here that caspase-3 could be regulated
through post-translational modifications. For instance, cellular in-
hibitor of apoptosis (cIAP1) dependent ubiquitylation of active subunits
of caspase-3, p12 and p17, leads to proteasome-dependent degradation
of these effector caspases. These findings show that disabling the ubi-
quitin-proteasome pathway could induce apoptosis by stabilizing the
active caspase-3 subunits [30]. Interestingly, in HF28GFP and HF28Bcl-
xL cells, the combination of MG-132 and TRAIL led to the accumulation
of active caspase-3 subunits, p12 and p17 while there was still a sig-
nificant amount of an intermediate caspase-3 form, p20. It is, therefore,
likely that MG-132 stabilized p12 and p17 from degradation and
thereby enhancing apoptosis.
Bortezomib (PS-314) is a first-in-class proteasome inhibitor, which
is used in clinics for the treatment of mantle cell lymphoma and mul-
tiple myeloma. In addition to its direct action, bortezomib enhances the
standard chemotherapy or radiotherapy treatment. Moreover, a new
class of proteasome inhibitors such as carfilzomib and marizomib have
been developed to increase the efficiency of proteasome inhibition
while decreasing its side-effects [31,32]. We, therefore, suggest that the
combination of TRAIL and a highly selective proteasome inhibitor
might be beneficial to treat lymphoma patients.
In conclusion, we demonstrate that the combination of MG-132 with
TRAIL induces apoptosis in TRAIL-resistant HF28Bcl-xL cells partly
through the accumulation of Bim and Bid cleavage products, jBid and
tBid. In addition, it seems that the production of jBid is dependent on
the membrane potential status of a cell because jBid is only produced
when mitochondrial depolarization is fully prevented or the proportion
of cells with depolarized membrane is minimal. Furthermore, given the
specificity of TRAIL against cancer cells, the combination of TRAIL
agonists with highly specific proteasome inhibitors might be an effec-
tive treatment strategy for patients with relapsed/TRAIL refractory
lymphomas.
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